IL-18 is an established biomarker of heart failure, so that it has been proposed that anti-IL-18 treatment may have therapeutic effects in patients with SCD at risk for cardiac arrhythmias and adverse outcomes (30). This evidence concerns the gene IL18 and heart failure.